Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy

Clinical Endocrinology

Volumn 74, Issue 3, 2011, Pages 377-383

  Hamilton, E J ^a   Gianatti, E ^a   Strauss, B J ^b   Wentworth, J ^c   Lim Joon, D ^d   Bolton, D ^a   Zajac, J D ^a   Grossmann, M ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d AUSTIN HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANTIANDROGEN; C PEPTIDE; ESTRADIOL; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; SEX HORMONE BINDING GLOBULIN; STEROID; TESTOSTERONE; TRIACYLGLYCEROL;

ABDOMINAL SUBCUTANEOUS FAT; ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BLOOD SAMPLING; BODY COMPOSITION; BODY FAT DISTRIBUTION; BODY MASS; CANCER PATIENT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HORMONE DEFICIENCY; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LEAN BODY WEIGHT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PATIENT REFERRAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RISK FACTOR; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ANALYSIS OF VARIANCE; ANDROGEN ANTAGONISTS; ESTRADIOL; HUMANS; IMMUNOASSAY; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; LINEAR MODELS; MALE; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; SUBCUTANEOUS FAT, ABDOMINAL; TESTOSTERONE; TIME FACTORS;

EID: 79851506306     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2010.03942.x     Document Type: Article

References (39)

1. Smith, M.R., (2007) Androgen deprivation therapy for prostate cancer: new concepts and concerns. Current Opinion in Endocrinology, Diabetes, and Obesity, 14, 247-254. (Pubitemid 46684481)
2. Basaria, S., (2008) Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth. Journal of Andrology, 29, 534-539.
3. Grossmann, M., Hamilton, E.J., Gilfillan, C., et al. (2010) Bone and Metabolic Health in Patients with Prostate Cancer Receiving Androgen Deprivation Therapy-Management Guidelines on behalf of the Endocrine Society of Australia, the Australian and New Zealand Bone and Mineral Society, and the Urological Society of Australia and New Zealand. Medical Journal of Australia, in press.
4. Shahinian, V.B., Kuo, Y.F., Freeman, J.L., et al. (2005) Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer, 103, 1615-1624. (Pubitemid 40490022)
5. Lu-Yao, G., Stukel, T.A., &, Yao, S.L., (2004) Changing patterns in competing causes of death in men with prostate cancer: a population based study. Journal of Urology, 171, 2285-2290. (Pubitemid 38625453)
6. Grossmann, M., Thomas, M.C., Panagiotopoulos, S., et al. (2008) Low testosterone levels are common and associated with insulin resistance in men with diabetes. Journal of Clinical Endocrinology and Metabolism, 93, 1834-1840. (Pubitemid 351656526)
7. Bhasin, S., Cunningham, G.R., Hayes, F.J., et al. (2010) Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism, 95, 2536-2559.
8. Smith, J.C., Bennett, S., Evans, L.M., et al. (2001) The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. Journal of Clinical Endocrinology and Metabolism, 86, 4261-4267. (Pubitemid 32848544)
9. Basaria, S., Lieb 2nd, J., Tang, A.M., et al. (2002) Long-term effects of androgen deprivation therapy in prostate cancer patients. Clinical Endocrinology, 56, 779-786. (Pubitemid 34785910)
10. Smith, M.R., Lee, H., &, Nathan, D.M., (2006) Insulin sensitivity during combined androgen blockade for prostate cancer. Journal of Clinical Endocrinology and Metabolism, 91, 1305-1308.
11. Keating, N.L., O'Malley, A.J., &, Smith, M.R., (2006) Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. Journal of Clinical Oncology, 24, 4448-4456. (Pubitemid 46630983)
12. Shahani, S., Braga-Basaria, M., &, Basaria, S., (2008) Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. Journal of Clinical Endocrinology and Metabolism, 93, 2042-2049. (Pubitemid 351831513)
13. Ronti, T., Lupattelli, G., &, Mannarino, E., (2006) The endocrine function of adipose tissue: an update. Clinical Endocrinology, 64, 355-365.
14. Grossmann, M., Gianatti, E.J., &, Zajac, J.D., (2010) Testosterone and type 2 diabetes. Current Opinion in Endocrinology, Diabetes, and Obesity, 17, 247-256.
15. Dhindsa, S., Miller, M.G., McWhirther, C.L., et al. (2010) Testosterone concentrations in diabetic and nondiabetic obese men. Diabetes Care, 33, 1186-1192.
16. Schroeder, E.T., Zheng, L., Ong, M.D., et al. (2004) Effects of androgen therapy on adipose tissue and metabolism in older men. Journal of Clinical Endocrinology and Metabolism, 89, 4863-4872. (Pubitemid 39391420)
17. Allan, C.A., Strauss, B.J., Burger, H.G., et al. (2008) Testosterone Therapy Prevents Gain in Visceral Adipose Tissue and Loss of Skeletal Muscle in Nonobese Aging Men. Journal of Clinical Endocrinology and Metabolism, 93, 139-146.
18. Svartberg, J., Agledahl, I., Figenschau, Y., et al. (2008) Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. International Journal of Impotence Research, 20, 378-387.
19. Smith, M.R., Finkelstein, J.S., McGovern, F.J., et al. (2002) Changes in body composition during androgen deprivation therapy for prostate cancer. Journal of Clinical Endocrinology and Metabolism, 87, 599-603. (Pubitemid 34158224)
20. Hamilton, E.J., Ghasem-Zadeh, A., Gianatti, E., et al. (2010) Structural Decay of Bone Microarchitecture in Men with Prostate Cancer treated with Androgen Deprivation Therapy. Journal of Clinical Endocrinology and Metabolism, 95, E456-E463.
21. Wentworth, J.M., Naselli, G., Brown, W.A., et al. (2010) Pro-inflammatory CD11c+CD206+ adipose tissue macrophages are associated with insulin resistance in human obesity. Diabetes, 59, 1648-1656.
22. Sikaris, K., McLachlan, R.I., Kazlauskas, R., et al. (2005) Reproductive hormone reference intervals for healthy fertile young men: evaluation of automated platform assays. Journal of Clinical Endocrinology and Metabolism, 90, 5928-5936. (Pubitemid 41606507)
23. Team, R.D.C., (2007) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL www.r-project.org/foundation/
24. Levine, G.N., D'Amico, A.V., Berger, P., et al. (2010) Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation, 121, 833-840.
25. Sato, T., Matsumoto, T., Yamada, T., et al. (2003) Late onset of obesity in male androgen receptor-deficient (AR KO) mice. Biochemical and Biophysical Research Communications, 300, 167-171. (Pubitemid 36042946)
26. Abate, N., Haffner, S.M., Garg, A., et al. (2002) Sex steroid hormones, upper body obesity, and insulin resistance. Journal of Clinical Endocrinology and Metabolism, 87, 4522-4527. (Pubitemid 35247035)
27. Tsai, E.C., Matsumoto, A.M., Fujimoto, W.Y., et al. (2004) Association of bioavailable, free, and total testosterone with insulin resistance: influence of sex hormone-binding globulin and body fat. Diabetes Care 27, 861-868. (Pubitemid 38420205)
28. Bojesen, A., Kristensen, K., Birkebaek, N.H., et al. (2006) The metabolic syndrome is frequent in Klinefelter's syndrome and is associated with abdominal obesity and hypogonadism. Diabetes Care, 29, 1591-1598. (Pubitemid 44127586)
29. Khaw, K.T., &, Barrett-Connor, E., (1992) Lower endogenous androgens predict central adiposity in men. Annals of Epidemiology, 2, 675-682.
30. Tsai, E.C., Boyko, E.J., Leonetti, D.L., et al. (2000) Low serum testosterone level as a predictor of increased visceral fat in Japanese-American men. International Journal of Obesity and Related Metabolic Disorders, 24, 485-491. (Pubitemid 30198102)
31. Yialamas, M.A., Dwyer, A.A., Hanley, E., et al. (2007) Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. Journal of Clinical Endocrinology and Metabolism, 92, 4254-4259. (Pubitemid 350074740)
32. Pitteloud, N., Mootha, V.K., Dwyer, A.A., et al. (2005) Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care, 28, 1636-1642. (Pubitemid 41340902)
33. Brennan, A.M., &, Mantzoros, C.S., (2006) Drug Insight: the role of leptin in human physiology and pathophysiology-emerging clinical applications. Nature Clinical Practice Endocrinology & Metabolism, 2, 318-327. (Pubitemid 43885911)
34. Koerner, A., Kratzsch, J., &, Kiess, W., (2005) Adipocytokines: leptin-the classical, resistin-the controversical, adiponectin-the promising, and more to come. Best Practice & Research. Clinical Endocrinology & Metabolism, 19, 525-546. (Pubitemid 41819217)
35. Bottner, A., Kratzsch, J., Muller, G., et al. (2004) Gender differences of adiponectin levels develop during the progression of puberty and are related to serum androgen levels. Journal of Clinical Endocrinology and Metabolism, 89, 4053-4061. (Pubitemid 39071513)
36. Lanfranco, F., Zitzmann, M., Simoni, M., et al. (2004) Serum adiponectin levels in hypogonadal men: influence of testosterone replacement therapy. Clinical Endocrinology, 60, 500-507. (Pubitemid 38482514)
37. Kapoor, D., Clarke, S., Stanworth, R., et al. (2007) The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. European Journal of Endocrinology, 156, 595-602. (Pubitemid 46796527)
38. Smith, M.R., Lee, H., McGovern, F., et al. (2008) Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer, 112, 2188-2194. (Pubitemid 351628628)
39. Dandona, P., Aljada, A., Chaudhuri, A., et al. (2005) Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation, 111, 1448-1454. (Pubitemid 40396812)